WiseTech Global Ltd (ASX: WTC) shares fell heavily yesterday, plummeting 18% to levels last seen back in 2021.

Media reports state that the Australian Federal Police are investigating founder Richard White over alleged trafficking matters, relating to a former cleaner at WiseTech.

It has been claimed that White exploited the woman’s immigration status and financial position and provided false information on a visa application.

WiseTech has not responded to the reports.

Why this is hitting WiseTech shares so hard

White’s continued prominence at the company makes today’s news particularly significant for shareholders.

WiseTech shares are now down more than 56% since the start of 2026 and around 70% lower than this time last year.

White co-founded WiseTech and served as chief executive until October 2024, before stepping down amid separate allegations relating to inappropriate behaviours.

He was later appointed Executive Chair and Chief Innovation Officer in February 2025 under a ten-year employment agreement. In this role, he retained significant influence over the company’s product development and strategic direction.

A pattern of governance concerns

Today’s allegations land on top of an already difficult governance backdrop.

In October 2025, the ABC reported that ASIC and the AFP had searched a WiseTech office as part of a separate investigation into alleged trading in WiseTech shares by White and three employees.

Macquarie noted that this investigation could take up to 18 months to resolve.

That earlier search triggered board turnover, including the resignation of four independent non-executive directors, and sustained media scrutiny that has weighed on investor confidence ever since.

The company is also midway through a major restructuring tied to AI-driven automation across the business.

Each of these issues alone could be manageable. Together, and now compounded by today’s allegations, they have eroded the institutional confidence that previously supported WiseTech’s premium valuation.

What the underlying business looks like

CargoWise generated US$682.2 million in revenue for WiseTech in FY2025. This is up 18% on the prior year, with growth continuing into FY2026 as first-half CargoWise revenue rose 12% to US$372.4 million.

CargoWise remains deeply embedded in the operations of major global freight forwarders. Switching away from the platform is expensive and disruptive for customers, providing a source of revenue stability even amid the governance turmoil.

The operational business and the governance crisis are, for now, two separate stories.

What happens next

The resolution of today’s news will depend heavily on the outcome of any AFP investigation and on how WiseTech’s board responds.

Bell Potter previously argued the worst was behind WiseTech following earlier governance issues. The broker noted that focus was returning to product momentum and a new commercial model, before today’s fresh allegations reset that narrative entirely.

Until clarity emerges on both the legal matter and the board’s response, WiseTech shares are likely to remain volatile, and investors should treat any near-term share price movements with appropriate caution given the seriousness and unresolved nature of the allegations.

Foolish takeaway

Today’s news is serious. WiseTech’s underlying logistics software business continues to perform, but the company’s governance challenges have now reached a new and more serious level.

Investors considering WiseTech shares may want to wait for greater clarity on both the AFP investigation and the board’s response before drawing firm conclusions about the path ahead.

The post WiseTech shares just crashed. Can investors look past the company’s governance issues? appeared first on The Motley Fool Australia.

More reading

• Why Humm, Metcash, PLS, and WiseTech shares are sinking today
• WiseTech shares crash 12% as founder scandal deepens
• Down but not out: 3 ASX tech shares ripe for a rebound
• Is the only way up for WiseTech shares after a 65% fall?
• How to know when a beaten-down ASX share is worth buying

Motley Fool contributor Mark Verhoeven has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended WiseTech Global. The Motley Fool Australia has positions in and has recommended WiseTech Global. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

If you are looking for ASX dividend shares to buy, then it could be worth considering the one in this article.

That’s because Bell Potter believes it has the potential to offer both major upside and a very generous dividend yield.

Which ASX dividend share?

The dividend share that Bell Potter is recommending to clients is Regal Partners Ltd (ASX: RPL).

It is a growing boutique asset manager that manages a number of alternative investment strategies, investing across hedge funds, growth equity, credit and royalties, and real and natural assets.

Bell Potter is positive on the company’s outlook and has lifted its earnings estimates to reflect its expectation for further funds under management growth. In fact, it believes the ASX dividend share could grow earnings in the teens over the medium term. It explains:

We upgrade EPS and retain our Buy rating. Regal Partners is an alternative investment manager, housing eight separate primary brands with a heritage in long/short equities. Strategies have track records that predate the global financial crisis. The Group controls $21bn in funds under management. We see further growth, driven by positive net inflows, investment performance, acquisitions and exposure to secular asset classes. This is supported by an aspirational blueprint to double offshore client capital.

Successful execution, in our view, provides a pathway to teens growth over the medium term, enhanced through operating leverage. A strong balance sheet further de-risks that view. Regal Partners has $250m in available capital. We see it well positioned to recycle capital, generating higher return, locking in gains and distributing this to shareholders.

Time to buy

According to the note, Bell Potter has reinstated its buy rating and $4.70 price target on the ASX dividend share.

Based on its current share price of $2.91, this implies potential upside of over 60% for investors over the next 12 months.

In addition, the broker is forecasting fully franked dividends of 18 cents per share in FY 2026, 19 cents per share in FY 2027, and then 22 cents per share in FY 2028. This equates to big dividend yields of 6.2%, 6.5%, and 7.6%, respectively.

Commenting on its investment thesis, Bell Potter said:

Our Buy is reinstated, and we hold our target price at $4.70/sh based on a DCF. We use global asset manager P/E multiples as a cross-check, with the cohort trading on an average 15x including 11x for long-equities, 15x for private markets/credit and 19x for comparable multi-boutiques and hedge funds. To that end, we see the valuation as undemanding.

Trading on 10x earnings, RPL does not screen as an alternative investment manager. We view the emerging evidence of performance fees, capital management and broadening investment strategies as an opportunity to narrow the discount and drive a re-rating in the stock.

The post Could this be the best ASX dividend share to buy now? appeared first on The Motley Fool Australia.

More reading

• How I’d aim for $10,000 a year in superannuation boosting passive income buying ASX shares

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

ASX All Ords healthcare share Monash IVF Group Ltd (ASX: MVF) has enjoyed a solid rebound since getting hammered in March and April 2025.

Trading for 72 cents a share in late afternoon trade on Monday, Monash IVF shares have gained more than 22% since market close on 19 November. For some context, the All Ordinaries Index (ASX: XAO) has gained 3.6% over this same time.

Atop that share price rebound, Monash IVF also paid out a 1.2 cent per share fully franked dividend to eligible stockholders on 10 April.

If we add that back in to Tuesday’s share price, then the accumulated value of the stock is up 24.1% since 19 November.

Looking ahead, however, Bell Potter Securities’ Christopher Watt forecasts a more difficult run over the coming months (courtesy of The Bull).

Time to exit this ASX All Ords healthcare share?

“The fertility services company recently downgraded fiscal year 2026 guidance,” Watt said. “It now expects underlying net profit after tax [NPAT] to range between $17 million and $18 million.”

Monash IVF reported that adjustment, down from prior FY 2026 NPAT guidance of $20 million, on 12 June.

Management noted that the primary driver for the lowered FY 2026 earnings outlook was lower than expected Australian assisted reproductive technology (ART) market activity in the second half of the financial year.

Addressing the slowdown, Monash IVF CEO Victoria Atkinson said “Monash IVF has increased its Australian stimulated cycle market share during this period and has taken steps to reduce costs and improve operational performance.”

But Bell Potter’s Watt still foresees potential headwinds over the medium-term.

Summarising his sell recommendation on the ASX All Ords healthcare share, Watt said:

Across the Australian market, stimulated cycle volumes were down 4.7% on a rolling three-month basis to the end of April when compared to the prior corresponding period. Cost-of-living pressures and declining birth rates are structural headwinds for the whole industry.

New leadership has a genuine reset opportunity, but until there’s evidence of an industry-wide recovery, I remain cautious.

Consider this surging ASX stock instead

Rather than buying ASX All Ords healthcare share Monash IVF, Watt recommended that investors consider buying ASX energy services provider GenusPlus Group (ASX: GNP)

“GNP appeals following the acquisition of MPC Kinetic Holdings, which broadens the business beyond electrical infrastructure and into gas, water and renewable energy services,” he said.

Summarising his buy recommendation on GenusPlus shares, Watt concluded:

The deal adds scale, recurring customer relationships and complementary civil capability, while also improving the earnings outlook. With upgraded guidance, manageable leverage and exposure to major infrastructure investment, GenusPlus remains well placed to deliver growth from existing operations and future contract wins.

With a strong contracted position and the tailwind of tighter east-coast gas, I believe there’s still upside to consensus.

As of late trade on Monday, GenusPlus shares are up 180% over the past 12 months.

The post Up 21% since November, should I buy this dividend paying ASX All Ords healthcare share today? appeared first on The Motley Fool Australia.

More reading

• 3 ASX healthcare shares to sell despite signs of sector rebound
• Down 50%: Is this ASX stock a buy?
• Up 200%! Is it too late to buy this ASX stock? Bell Potter says it isn’t

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended GenusPlus Group. The Motley Fool Australia has recommended GenusPlus Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.